» Articles » PMID: 17446349

Mortality Rates, Life Expectancy, and Causes of Death in People with Hemophilia A or B in the United Kingdom Who Were Not Infected with HIV

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2007 Apr 21
PMID 17446349
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Since the 1970s, mortality in the hemophilia population has been dominated by human immunodeficiency virus (HIV) and few reports have described mortality in uninfected individuals. This study presents mortality in 6018 people with hemophilia A or B in the United Kingdom during 1977 to 1998 who were not infected with HIV, with follow-up until January 1, 2000. Given disease severity and factor inhibitor status, all-cause mortality did not differ significantly between hemophilia A and hemophilia B. In severe hemophilia, all-cause mortality did not change significantly during 1977 to 1999. During this period, it exceeded mortality in the general population by a factor of 2.69 (95% confidence interval [CI]: 2.37-3.05), and median life expectancy in severe hemophilia was 63 years. In moderate/mild hemophilia, all-cause mortality did not change significantly during 1985 to 1999, and median life expectancy was 75 years. Compared with mortality in the general population, mortality from bleeding and its consequences, and from liver diseases and Hodgkin disease, was increased, but for ischemic heart disease it was lower, at only 62% (95% CI: 51%-76%) of general population rates, and for 14 other specific causes it did not differ significantly from general population rates. There was no evidence of any death from variant Creutzfeldt-Jakob disease or from conditions that could be confused with it.

Citing Articles

Incidence and treatment-related risk factors of inhibitor development after intensive FVIII replacement for major orthopaedic surgery in previous treated haemophilia A.

Wang H, Zhu W, Wang S, Feng B, Weng X J Orthop Surg Res. 2024; 19(1):358.

PMID: 38880904 PMC: 11181571. DOI: 10.1186/s13018-024-04843-4.


Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes.

Dolan G, Fijnvandraat K, Lenting P, Catarino C, Lavin M Semin Thromb Hemost. 2024; 51(1):58-67.

PMID: 38733982 PMC: 11750352. DOI: 10.1055/s-0044-1786358.


Haemophilia and Cancer: A Literature Review.

Zanon E, Porreca A, Simioni P J Clin Med. 2024; 13(6).

PMID: 38541994 PMC: 10970836. DOI: 10.3390/jcm13061770.


Strabismus Surgery in Hemophilia: A Novel Surgical Technique and Guideline Recommendations.

Ismail M, Alsaedi A, Paysse E Cureus. 2024; 15(12):e51022.

PMID: 38269238 PMC: 10806410. DOI: 10.7759/cureus.51022.


Current Status and Challenges in Delivering Comprehensive Care for Patients with Hemophilia.

Nomura S J Blood Med. 2023; 14:629-637.

PMID: 38125786 PMC: 10730945. DOI: 10.2147/JBM.S446204.